

# REQUEST FOR PROPOSAL: ASSESSING THE ECONOMIC CONTRIBUTION OF GLOBAL HEALTH R&D IN THE UK

February 2025

**DEADLINE FOR SUBMISSIONS: 7<sup>TH</sup> MARCH 2025**

## About Malaria No More UK (MNMUK)

Malaria has been described as the oldest killer disease in history. Even now, despite recent progress, it claims the life of a child every minute.

Malaria No More UK (MNMUK) brings proven global experience and expertise in advocacy and creative communications to the zero-malaria fight. From our locations in London, UK and Nairobi, Kenya we aim to accelerate an end to this deadly disease by:

- Securing leadership and investment globally and in the UK
- Building a powerful, united voice for the global malaria campaign to hold leaders to account
- Strengthening local advocacy capacity in key countries in Africa

## Research Overview

Malaria remains a significant global challenge, with the disease responsible for almost 600,000 deaths annually.<sup>1</sup> As we approach key global health financing moments – including the next UK spending review – the case for continued investment in malaria needs to be robust, data-driven, and aligned with broader government priorities. The UK has a long history of leadership in malaria science, from early breakthroughs in understanding the disease to pioneering the latest innovations in diagnostics, treatment, and vaccines. However, with increasing pressure on aid budgets, there is a growing need to demonstrate not only the direct health benefits of malaria research and programmes but also the wider economic and strategic value of sustained UK engagement.

This research project seeks to quantify the economic and scientific benefits of the UK's role in malaria research, development, and control efforts. By examining the macroeconomic contribution of global health R&D, we aim to provide a compelling case for sustained UK investment in malaria, positioning it as both a global health priority and a driver of economic growth, innovation, and international influence. We aim to demonstrate how the Global Fund's support creates a market for UK-driven malaria R&D, strengthening the domestic economy. We also wish to highlight the return on investment of the UK's global health leadership, reinforcing the case for sustained or increased contributions to the Global Fund.

Through this research, we aim to generate robust evidence that supports policy recommendations, particularly in the context of the UK’s spending review and future international health commitments. By articulating the broader value of global health R&D investments, we seek to ensure that the UK remains at the forefront of the global fight against malaria while securing economic and strategic benefits at home.

The report will focus solely on the methodology and the quantitative results, providing the calculated figures and a clear explanation of how they were derived. A brief literature review is to be included to outline the sources used. This analysis will contribute to a broader report that MNMUK will produce, building on the findings presented.

## Research Objectives

To quantify the broader economic impact of global health R&D in the UK, focusing on contributions to GDP, job creation, and life sciences innovation.

- If possible, to quantify the impact of malaria R&D to the UK economy, similarly focusing on contributions to GDP, job creation, and life sciences innovation.
- Qualify what ‘global health’ means in this context, i.e. what is included in global health.

## Proposed Methodology

Economic analysis:

- To create a definition of ‘global health’ R&D
- To quantify what global health R&D has brought into the UK economy (building on existing research that quantifies this for all R&D (estimated at [\\$13 billion a year](#))).

## Expected deliverables

Short report (5-10 pages) including:

1. Quantitative research results
2. Brief literature review
3. Key messages and key arguments
4. Methodology
5. List of references
6. List of data sources

## Anticipated timeframe

Phase	Activity	Timeframe (weeks)	Date
-------	----------	-------------------	------

<b>Inception</b>	<ul style="list-style-type: none"> <li>- Kick off meeting</li> <li>- Agreement on scope and research methodology</li> <li>- Workshop on defining 'global health'</li> </ul>	2	w/c 17 <sup>th</sup> March
<b>Quantitative research</b>	<ul style="list-style-type: none"> <li>- Quantitative research</li> </ul>	3	31st March - 18 <sup>th</sup> April
<b>Finalising of quantitative research</b>	<ul style="list-style-type: none"> <li>- Evidence synthesis</li> <li>- Draft research paper</li> </ul>	1	w/c 21 <sup>st</sup> April
<b>Completion</b>	<ul style="list-style-type: none"> <li>- Final research paper and closing meeting</li> </ul>	1	w/c 28 <sup>th</sup> April
<b>Total</b>		7	

## Research oversight

The consultancy will be overseen by the Policy Officer, Ashleigh Huddart. In addition to oversight, MNMUK will extend the following support to the consultancy:

- Providing research and evidence already known
- Reviewing all deliverables and providing feedback before sign offs

## Selection criteria

MNMUK invites applications from consultancies and research organisations with relevant experience and expertise to undertake the assignment. The general criteria for selecting the firm include:

- Extensive experience in undertaking similar research globally and/or in the UK
- Organisational, analytical and communication skills (verbal and written)
- Fluency in English (verbal and written)
- Previous research experience in the field of malaria (preferred)
- African-based research organisation/consultancy (preferred)

## Expressions of interest submission

- Research proposal outlining how the research would be conducted
- CVs of researchers involved

- Example of previous work that is similar

Please send the above to [recruitment@malariaanomore.org.uk](mailto:recruitment@malariaanomore.org.uk) before 7th March 2025.

---

<sup>1</sup> World Health Organization (WHO), 2024. *World malaria report 2024*. [online] Available at: <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2024> [Accessed 11 February 2025].